Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible?
Poynard
Thierry
T
Thabut
Dominique
D
Chryssostalis
Ariane
A
Taieb
Julien
J
Ratziu
Vlad
V
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006519:Hepatitis, Alcoholic / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab